First Header Logo Second Header Logo

Connection

Kylie Kavanagh to Dose-Response Relationship, Drug

This is a "connection" page, showing publications Kylie Kavanagh has written about Dose-Response Relationship, Drug.
  1. Kavanagh K, Flynn DM, Nelson C, Zhang L, Wagner JD. Characterization and validation of a streptozotocin-induced diabetes model in the vervet monkey. J Pharmacol Toxicol Methods. 2011 May-Jun; 63(3):296-303.
    View in: PubMed
    Score: 0.083
  2. Kavanagh K, Flynn DM, Jenkins KA, Zhang L, Wagner JD. Restoring HSP70 deficiencies improves glucose tolerance in diabetic monkeys. Am J Physiol Endocrinol Metab. 2011 May; 300(5):E894-901.
    View in: PubMed
    Score: 0.083
  3. Kavanagh K, Brown KK, Berquist ML, Zhang L, Wagner JD. Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. Metabolism. 2010 Jun; 59(6):914-20.
    View in: PubMed
    Score: 0.077
  4. Wagner JD, Zhang L, Kavanagh K, Ward GM, Chin JE, Hadcock JR, Auerbach BJ, Harwood HJ. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. J Pharmacol Exp Ther. 2010 Oct; 335(1):103-13.
    View in: PubMed
    Score: 0.020
  5. Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, Harwood HJ. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther. 2010 Jun; 333(3):844-53.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.